Novel Antiplatelet Agents in Acute Coronary Syndrome

Dear Colleagues,

Platelet activation, adhesion, and aggregation represent key moments of thrombus formation at the site of atherosclerotic coronary plaques, causing the different clinical manifestations of acute coronary syndromes (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina). Accordingly, the use of antiplatelet agents has markedly improved the cardiovascular outcome in this clinical setting. However, despite the extensive use of the currently recommended platelet-inhibiting therapies, even dual or triple, there is a clear evidence that the residual risk of patients suffering an acute coronary syndrome yet remains elevated. Moreover, given the bleeding risk related to any antithrombotic treatment, the identification of novel antiplatelet therapies with the most favorable net clinical benefit (e.g., high protection from thrombotic events paying the lowest price in terms of bleeding complications) in acute coronary syndrome is welcome and needed, as it may have a significant impact on the recurrence of cardiovascular events and related mortality.

With this background in mind, the aim of this Special Issue of Journal of Clinical Medicine is to collect both experimental and clinical manuscripts focused on novel antiplatelet agents in acute coronary syndromes. We would like to receive studies exploring molecular mechanisms and pharmacodynamic effects of novel antiplatelet drugs, as well as preclinical and clinical investigations with the use of these agents. The studies have to be well designed and conducted with a rigorous methodology. Indeed, the ultimate goal of this Special Issue is to improve the cardiovascular outcome of patients suffering an acute coronary syndrome.

In this Special Issue, we are making a call to action to stimulate researchers and clinicians to submit their most valuable studies on the abovementioned topic. Original investigations, review articles, and research letters are especially welcome. Case reports will not be considered.

Dr. Giuseppe Patti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ST-segment elevation myocardial infarction
• Non-ST-segment elevation myocardial infarction
• Unstable angina
• Inhibitors of thromboxane synthesis
• P2Y12 inhibitors
• Thrombin-receptor antagonists
• Anti-Xa agents (antiplatelet effects)
• Glycoprotein IIb-IIIa antagonists